Quick China dealmaking as TVM, Lummy tie with Argos on oncology candidate
TVM Capital Life Science moved quickly to tap a new $50 million venture capital fund with investment from Chinese partner Lummy Co. in a licensing deal for an oncology dendritic vaccine.
Argos gets a $40M China deal for AGS-003
China's Lummy HK and the China BioPharma Capital I Fund have agreed to acquire $10 million worth of Durham, NC-based Argos Therapeutics stock in exchange for rights to develop and commercialize Argos' AGS-003 personalized cancer drug in China, Hong Kong, Taiwan and Macau.
Argos tanks as its HIV immunotherapy flunks Phase II
Argos Therapeutics' HIV treatment failed to meet its main goal in a midstage trial, raising concerns about the company's platform technology and sending its shares spiraling downward.
Argos starts work on $57M plant in North Carolina
Argos Therapeutics, which has a personalized immunotherapy drug to treat renal cell carcinoma in trials, has kicked off work on a $57 million manufacturing facility in North Carolina. The biotech will get nearly $10 million in public support for the project.
Biotech's breathless quarter of IPOs brings in $2.1B for R&D;
Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom.
IPO boom: 8 biotechs bag half a billion in a banner week
North Carolina's Argos Therapeutics raked in $45 million in a below-its-range Wall Street debut, sticking a so-so endcap on an otherwise colossal week for biotech IPOs in which drug developers banked more than $500 million.
Argos to test investor appetite for cancer vaccines with a $60M IPO
While Dendreon fell well short of serving as a good example of how cancer vaccine businesses can succeed on the public markets, it did at least provide a horrible warning of what can go wrong. Argos Therapeutics is undeterred though and has revived its IPO plans.
Argos swings for a $60M IPO in the shadow of Dendreon's struggles
North Carolina's Argos Therapeutics believes it can succeed where Dendreon has faltered, pitching a $60 million IPO that would help the biotech get its personalized cancer therapy through Phase III.
Argos rakes in $17.5M more to wrap up PhIII for cancer drug
Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get its kidney cancer candidate through Phase III and prove the promise of its dendritic cell platform.
Argos turns to unusual players for $42.5M needed to fund PhIII cancer study
With a Phase III cancer immunotherapy study under way, Durham, NC-based Argos Therapeutics today put in place its fifth fundraising, banking $42.5 million from a big group of backers led by a pair of unorthodox players.